
Allogene CEO to Step Down; Agios Drug Fails Key Test in Pharma Industry News
David Chang is set to depart from his role at the cell therapy maker Allogene after an eight-year tenure. In other developments, a next-generation blood disease drug faced setbacks, while an acquisition by AbbVie led to an FDA approval. These updates provide valuable insights into the pharmaceutical industry landscape and its impact on American healthcare and innovation.











